PCRXHIGH SIGNALOPERATIONAL10-K

PCRX has pivoted from the iovera platform to focus on PCRX-201, while substantially reducing debt and current liabilities alongside meaningful revenue growth.

The shift from iovera to PCRX-201 in risk disclosures suggests a major strategic repositioning of the company's product portfolio. The removal of Flexion acquisition-related risks combined with substantial debt reduction indicates successful integration and deleveraging, though the company is investing heavily in R&D for its new focus area.

Comparing 2026-02-26 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

PCRX demonstrated strong operational performance with 26% revenue growth while dramatically improving its balance sheet through substantial reductions in debt (-36.4%) and current liabilities (-61.1%). The company increased R&D spending meaningfully to support its strategic pivot, though this was partially offset by lower interest expenses due to debt reduction. Despite using cash for operations and debt paydown, the overall financial picture reflects a company successfully executing a strategic transformation while maintaining growth momentum.

FINANCIAL STATEMENT CHANGES
Current Liabilities
Balance Sheet
-61.1%
$309.9M→$120.6M

Current liabilities reduced — improved short-term financial position and working capital health.

Interest Expense
P&L
-49.2%
$40.0M→$20.3M

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Capital Expenditure
Cash Flow
+44.2%
$10.6M→$15.3M

Capital expenditure jumped 44.2% — major investment cycle underway; assess returns on deployment.

R&D Expense
P&L
+43.8%
$81.6M→$117.3M

R&D investment increased 43.8% — signals commitment to future product development, though near-term margin impact.

Cash & Equivalents
Balance Sheet
-42.7%
$276.8M→$158.5M

Cash declined 42.7% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Total Debt
Balance Sheet
-36.4%
$585.3M→$372.2M

Debt reduced 36.4% — deleveraging strengthens balance sheet and reduces financial risk.

Current Assets
Balance Sheet
-26.5%
$745.1M→$548.0M

Current assets declined 26.5% — monitor working capital adequacy and short-term liquidity.

Total Liabilities
Balance Sheet
-26.2%
$775.2M→$571.8M

Liabilities reduced 26.2% — deleveraging improves balance sheet strength and financial flexibility.

Revenue
P&L
+26%
$429.6M→$541.5M

Revenue growing 26% — solid top-line momentum, watch margins for quality of growth.

SG&A Expense
P&L
+25.4%
$294.1M→$368.8M

SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-27
ADDED
As of February 23, 2026, 40,489,894 shares of the registrant s common stock, $0.001 par value per share, were outstanding.
That supply chain disruptions could interrupt product manufacturing and global logistics and increase product costs.
That we make substantial investments in research and development, or R D, and if those investments are unsuccessful, it could materially adversely affect our business, financial condition and results of operations.
That we are subject to periodic litigation, which could result in losses or unexpected expense of time and resources.
That the patents and the patent applications that we have covering PCRX-201 are limited.
+7 more — sign up free →
REMOVED
As of February 25, 2025, 46,276,241 shares of the registrant s common stock, $0.001 par value per share, were outstanding.
That we make substantial investments in research and development and if those investments are unsuccessful, it could materially adversely affect our business, financial condition and results of operations.
That the patents and the patent applications that we have covering iovera are limited.
Our inability to realize the benefits from the Flexion Acquisition (as defined below), being substantially dependent on the commercial success of ZILRETTA and the cost savings resulting from the timely and effective integration of the operations of Pacira and Flexion (as defined below).
The use of our net operating loss carryforwards and research and development tax credits being limited.
+7 more — sign up free →
MORE OPERATIONAL SIGNALS
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NOWHIGHServiceNow has fundamentally repositioned itself as an AI-first platform company...
2026-01-29
TSLAHIGHTesla has fundamentally repositioned itself from an electric vehicle company to ...
2026-01-29
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →